The CDKA-1 antibody (e.g., ab108290) is a recombinant monoclonal antibody targeting CDK2-associated protein 1 (CDK2AP1), also known as Deleted in Oral Cancer 1 (DOC1). This protein functions as an inhibitor of cyclin-dependent kinase 2 (CDK2) and is a component of the histone deacetylase NuRD complex, which regulates chromatin remodeling . CDKA-1 antibodies are primarily used in research to study cell cycle regulation, cancer biology, and epigenetic modifications.
Western Blot (WB): Detects endogenous CDK2AP1 in human cell lysates (e.g., HeLa, HUVEC, LNCaP) .
Mechanistic Studies: Investigates CDK2AP1’s role in tumor suppression, cell proliferation, and chromatin dynamics .
Functional Role: CDK2AP1 binds to CDK2, inhibiting its kinase activity and modulating cell cycle progression .
Cancer Relevance: Reduced CDK2AP1 expression correlates with oral and other cancers, suggesting its role as a tumor suppressor .
Structural Data: The antibody recognizes a 12 kDa protein band in human cell lines, consistent with CDK2AP1’s molecular weight .
Cell Line | Observed Band Size | Reactivity Confirmed |
---|---|---|
293T | 12 kDa | Yes |
HeLa | 12 kDa | Yes |
HUVEC | 12 kDa | Yes |
LNCaP | 12 kDa | Yes |
Source: ab108290 product validation .
CDK2AP1 regulates the G1/S transition by binding CDK2, preventing its interaction with cyclins and inhibiting phosphorylation of downstream targets like retinoblastoma (Rb) protein . This mechanism is critical for maintaining genomic stability and preventing uncontrolled proliferation.
As part of the NuRD complex, CDK2AP1 facilitates histone deacetylation, leading to chromatin condensation and transcriptional repression. Dysregulation of this process is implicated in cancer and developmental disorders .